- Home
- A-Z Publications
- CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders)
- Previous Issues
- Volume 15, Issue 5, 2016
CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders) - Volume 15, Issue 5, 2016
Volume 15, Issue 5, 2016
-
-
mTOR, a Potential Target to Treat Autism Spectrum Disorder
By Atsushi SatoMammalian target of rapamycin (mTOR) is a key regulator in various cellular processes, including cell growth, gene expression, and synaptic functions. Autism spectrum disorder (ASD) is frequently accompanied by monogenic disorders, such as tuberous sclerosis complex, phosphatase and tensin homolog tumor hamartoma syndrome, neurofibromatosis 1, and fragile X syndrome, in which mTOR is hyperactive. Mutation Read More
-
-
-
Modeling Rett Syndrome Using Human Induced Pluripotent Stem Cells
Authors: Tomoko Andoh-Noda, Michiko O. Inouye, Kunio Miyake, Takeo Kubota, Hideyuki Okano and Wado AkamatsuRett syndrome (RTT) is one of a group of neurodevelopmental disorders typically characterized by deficits in the X-linked gene MECP2 (methyl-CpG binding protein 2). The MECP2 gene encodes a multifunctional protein involved in transcriptional repression, transcriptional activation, chromatin remodeling, and RNA splicing. Genetic deletion of Mecp2 in mice revealed neuronal disabilities including RTT-like phenotypes and provid Read More
-
-
-
Effects of Yokukansan, a Japanese Kampo Medicine for Symptoms Associated Autism Spectrum Disorder
Authors: Rei Wake, Tsuyoshi Miyaoka, Motohide Furuya, Sadayuki Hashioka and Jun HoriguchiA neuropsychiatric syndrome, Autism spectrum disorder (ASD) is qualified via impairments in qualitative communication, social interaction, and stereotyped or restricted, repetitive patterns of behavior, interests, or activities. While all ASDs are considered to have qualitative deficits in social relatedness to others, many people with ASDs have other symptoms, including irritability (which includes aggression, self-injurious behav Read More
-
-
-
The Potential of Nasal Oxytocin Administration for Remediation of Autism Spectrum Disorders
Authors: Yuko Okamoto, Makoto Ishitobi, Yuji Wada and Hirotaka KosakaAdministration of oxytocin has been proposed as a treatment for the core symptoms of autism spectrum disorder (ASD), including social-communicative deficit. Previous clinical trials have investigated the efficacy and safety of oxytocin intranasal single-dose and long-term administration for individuals with ASD. All studies suggest that singledose and long-term administration are well tolerated, and no sever Read More
-
-
-
Psycho-Cognitive Intervention for ASD from Cross-Species Behavioral Analyses of Infants, Chicks and Common Marmosets
Authors: Mamiko Koshiba, Genta Karino, Koki Mimura, Shun Nakamura, Kunio Yui, Tetsuya Kunikata and Hideo YamanouchiEducational treatment to support social development of children with autism spectrum disorder (ASD) is an important topic in developmental psychiatry. However, it remains difficult to objectively quantify the socio-emotional development of ASD children. To address this problem, we developed a novel analytical method that assesses subjects’ complex behaviors using multivariate analysis, 'Behavior Output analysis fo Read More
-
-
-
Oxidative Stress and Nitric Oxide in Autism Spectrum Disorder and Other Neuropsychiatric Disorders
Authors: Kunio Yui, Yohei Kawasaki, Hiroshi Yamada and Shintaro OgawaThe etiology of autism spectrum disorder (ASD) remains unclear; however, the toxic environmental exposure to oxidative stress has been suggested to play an important role in its pathogenesis. A loss of balance between oxidative stress and antioxidant capacity produces an excess of reactive nitrogen species (RNS) such as nitric oxide (NO). Polyunsaturated fatty acids (PUFAs), particularly arachidonic acid, docosahexa Read More
-
-
-
Sulforaphane Treatment of Young Men with Autism Spectrum Disorder
Authors: Kanwaljit Singh and Andrew W. ZimmermanAutism Spectrum Disorder (ASD) comprises a heterogeneous group of neurodevelopmental disorders that begin in early childhood. They are characterized by differences in behavior and delays in communication and affect at least 1% of children. Observational studies have now confirmed that behaviors of a substantial percentage of children with autism tend to improve with the onset of febrile illness, which might be the d Read More
-
-
-
Biomarker-Guided Strategy for Treatment of Autism Spectrum Disorder (ASD)
Authors: Hua Liu, Paul Talalay and Jed W. FaheyAutism spectrum disorder (ASD) is a complex, life-long neurodevelopmental disorder currently affecting an estimated 1 out of 68 among children aged 8 y in the United States. ASD has complex genetic and epigenetic features that lead to the phenotype and there is no single genetic marker for the diagnosis. Therefore, the diagnosis for ASD is phenotype- based with no validated or credible laboratory tests available. Evidence Read More
-
-
-
Autism, Mitochondria and Polybrominated Diphenyl Ether Exposure
Authors: Sarah Wong and Cecilia GiuliviBackground: Autism spectrum disorders (ASD) are a growing concern with more than 1 in every 68 children affected in the United States by age 8. Limited scientific advances have been made regarding the etiology of autism, with general agreement that both genetic and environmental factors contribute to this disorder. Objective: To explore the link between exposure to PBDE, mitochondrial dysfunction and autism risk. Results: Read More
-
-
-
In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer’s Disease Treatment
Alzheimer’s disease (AD) is the most frequent cause of dementia, especially in the elderly. AD is the most common progressive neurodegenerative disorder, which involves the loss of structure and function of cholinergic neurons. Moreover, if these neuronal changes cannot be compensated, this may ultimately lead to neurodegenerative processes. Therefore, most of the drug therapies are based on the cholinergic hypothesis Read More
-
-
-
Establishment of Cell-Based Neuroglobin Promoter Reporter Assay for Neuroprotective Compounds Screening
Authors: Ning Liu, Zhanyang Yu, Xiumei Gao, Yun S. Song, Jing Yuan, Yu Xun, Tingting Wang, Feng Yan, Shishan Yuan, Jian Zhang, Shuanglin Xiang, Eng H. Lo and Xiaoying WangNeuroglobin (Ngb) has been demonstrated to be neuroprotective against stroke and neurodegenerative diseases, thus upregulating Ngb might be a novel approach for neuroprotection. In this study we aimed to establish cell-based Ngb reporter systems for screening neuroprotective compounds targeting Ngb upregulation. We developed both mouse and human stable Ngb reporter systems containing a luciferase reporter gene di Read More
-
Volumes & issues
-
Volume 24 (2025)
-
Volume 23 (2024)
-
Volume 22 (2023)
-
Volume 21 (2022)
-
Volume 20 (2021)
-
Volume 19 (2020)
-
Volume 18 (2019)
-
Volume 17 (2018)
-
Volume 16 (2017)
-
Volume 15 (2016)
-
Volume 14 (2015)
-
Volume 13 (2014)
-
Volume 12 (2013)
-
Volume 11 (2012)
-
Volume 10 (2011)
-
Volume 9 (2010)
-
Volume 8 (2009)
-
Volume 7 (2008)
-
Volume 6 (2007)
-
Volume 5 (2006)
Most Read This Month
Article
content/journals/cnsnddt
Journal
10
5
false
en

Most Cited Most Cited RSS feed
-
-
A Retrospective, Multi-Center Cohort Study Evaluating the Severity- Related Effects of Cerebrolysin Treatment on Clinical Outcomes in Traumatic Brain Injury
Authors: Dafin F. Muresanu, Alexandru V. Ciurea, Radu M. Gorgan, Eva Gheorghita, Stefan I. Florian, Horatiu Stan, Alin Blaga, Nicolai Ianovici, Stefan M. Iencean, Dana Turliuc, Horia B. Davidescu, Cornel Mihalache, Felix M. Brehar, Anca . S. Mihaescu, Dinu C. Mardare, Aurelian Anghelescu, Carmen Chiparus, Magdalena Lapadat, Viorel Pruna, Dumitru Mohan, Constantin Costea, Daniel Costea, Claudiu Palade, Narcisa Bucur, Jesus Figueroa and Anton Alvarez
-
-
-
- More Less